Trials / Recruiting
RecruitingNCT07516925
A Study of Ivonescimab in People With Leiomyosarcoma
Vonescimab for the Treatment of Previously Treated Advanced or Unresectable Leiomyosarcoma - a Phase II Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivonescimab | Ivonescimab is administered IV Q3W on Day 1 of each cycle |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2029-04-01
- Completion
- 2029-04-01
- First posted
- 2026-04-08
- Last updated
- 2026-04-08
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07516925. Inclusion in this directory is not an endorsement.